US EditionImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025
- ImmuneOncia Therapeutics, a South Korean biotech company, announced interim Phase 1b results of its CD47-targeting antibody IMC-002 with lenvatinib for advanced hepatocellular carcinoma at ASCO 2025 in Chicago.
- In 2021, ImmuneOncia licensed IMC-002 to 3D Medicines, a Chinese company, under an agreement valued at up to $470 million. The company plans to list on the KOSDAQ in May 2025 as part of its strategy to broaden its international reach in the field of immuno-oncology.
- IMC-002 blocks the CD47 'don't eat me' signal to enhance macrophage phagocytosis, showing a 30% partial response rate and 80% disease control rate among 10 evaluable patients, surpassing typical 10% second-line therapy responses for HCC.
- Analysis using AI-powered digital pathology demonstrated a 60% objective response rate among individuals exhibiting elevated CD47 levels on tumor cell membranes, compared to zero responses in those with lower levels, with this difference reaching statistical significance , highlighting CD47’s potential as a predictive biomarker.
- The study reported primarily Grade 1-2 adverse events, including mild anemia in 15% of patients, indicating that IMC-002 combined with lenvatinib may offer a novel approach to second-line HCC treatment by harnessing macrophage-based immunity.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
All
Left
1
Center
9
Right
Beatrice Daily Sun+16 Reposted by 16 other sources
ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025
CHICAGO, June 2, 2025 /PRNewswire/ -- ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with lenvatinib for patients with advanced hepatocellular carcinoma (HCC).…
Coverage Details
Total News Sources17
Leaning Left1Leaning Right0Center9Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
